Advertisement

Use of Monophosphoryl Lipid A as a Prophylactic for Sepsis and Shock

  • J. A. Rudbach
  • J. T. Ulrich
  • K. B. Von Eschen
  • J. D. Beatty

Abstract

Of patients who ultimately develop gram-negative sepsis and shock, many can be identified for inclusion into high-risk groups [1–3]. These groups include patients subjected to certain types of surgeries, some with traumatic injuries, and those with depressed immune systems. Appropriate immunomodulation of patients in these groups should be able to prevent or ameliorate septic shock.

Keywords

Septic Shock Continuous Ambulatory Peritoneal Dialysis Endotoxin Tolerance Monophosphoryl Lipid Serum Neopterin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kreger BE, Craven DE, Carling PC, McCabe WR (1980) Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med 68:344–355PubMedCrossRefGoogle Scholar
  2. 2.
    Luce JM (1987) Pathogenesis and management of septic shock. Chest 91:883–888PubMedCrossRefGoogle Scholar
  3. 3.
    Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ et al. (1989) Sepsis syndrome: a valid clinical entity. Crit Care Med 17:389–393PubMedCrossRefGoogle Scholar
  4. 4.
    Rudbach JA, Cantrell JL, Ulrich JT, Mitchell MS (1990) Immunotherapy with bacterial endotoxins. In: Friedman H, Klein TW, Nakaro M, Nowatny A (eds) Endotoxin. Plenum, New York, pp 665–676Google Scholar
  5. 5.
    Henricson BE, Benjamin WR, Vogel SN (1990) Differential cytokine induction by doses of lipopolysaccharide and monophosphoryl lipid A that result in equivalent early endotoxin tolerance. Infect Immun 58:2429–2437PubMedGoogle Scholar
  6. 6.
    Madonna GS, Peterson JE, Ribi EE, Vogel SN (1986) Early-phase endotoxin tolerance: induction by a detoxified lipid A derivative, monophosphoryl lipid A. Infect Immun 52:6–11PubMedGoogle Scholar
  7. 7.
    Kiener PA, Mark F, Rodgers G et al. (1988) Induction of tumor necrosis factor, IFN-α, and acute lethality in mice by toxic and non-toxic forms of lipid A. J immunol 141:870–874PubMedGoogle Scholar
  8. 8.
    Bennett JA, Peter JH, Chudacoff R, McKneally MF (1988) Endogenous production of cytotoxic factors in serum of BCG-primed mice by monophosphoryl lipid A, a detoxified form of endotoxin. J Biol Response Mod 7:65–76PubMedGoogle Scholar
  9. 9.
    Ulrich JT, Mashihi KN, Lange W (1988) Mechanisms of nonspecific resistance to microbial infections induced by trehalose dimycolate (TDM) and monophosphoryl lipid A (MPL). Adv Biosci 68:167–178Google Scholar
  10. 10.
    Mashihi KN, Lange W, Brehmer W, Ribi E (1986) Immunobiological activities of nontoxic lipid A: enhancement of nonspecific resistance in combination with trehalose dimycolate against viral infection and adjuvant effects. Int J Immunopharmacol 8:339–345CrossRefGoogle Scholar
  11. 11.
    Rackow EC, Astiz ME, Kim YB, Weil MH (1989) Monophosphoryl lipid A blocks the hemodynamic effects of lethal endotoxemia. J Lab Clin Med 113:112–117PubMedGoogle Scholar
  12. 12.
    Astiz ME, Rackow EC, Kim YB, Weil MA (1989) Hemodynamic effects of monophosphoryl lipid A compared to endotoxin. Circ Shock 27:193–198PubMedGoogle Scholar
  13. 13.
    Carozzi S, Salit M, Cantaluppi A et al. (1989) Effect of monophosphoryl lipid A on the in vitro function of peritoneal leukocytes from uremic patients on continuous ambulatory peritoneal dialysis. J Clin Microbiol 27:1748–1753PubMedGoogle Scholar

Copyright information

© Springer-Verlag, Berlin Heidelberg 1993

Authors and Affiliations

  • J. A. Rudbach
    • 1
  • J. T. Ulrich
    • 1
  • K. B. Von Eschen
    • 1
  • J. D. Beatty
    • 2
  1. 1.Ribi ImmunoChem Research, Inc.HamiltonUSA
  2. 2.Division of SurgeryCity of Hope National Medical CenterDuarteUSA

Personalised recommendations